Utang jangka cendhak marang modal asensus.com (ASXC)

Asensus Surgical, Inc. (ASXC) generates revenue through the sale and leasing of Senhance intelligent systems for minimally invasive surgery. However, chip supply chain disruptions and trade restrictions are hindering expansion into foreign markets. This chart illustrates the net debt-to-equity ratio, which stands at 0.00. The company is currently actively developing the innovative LUNA platform, completing the engineering design phase prior to large-scale testing.

The ratio of short-term liabilities to net equity determines the company's dependence on rapid refinancing, which reflects the risk of liquidity loss in the short-term debt-to-equity chart; calculating this metric by dividing current loans by shareholders' equity allows for an assessment of the stability of Asensus Surgical, Inc. (ASXC) during the development of energy-efficient surgical robots and the implementation of durable ESG solutions.